TopFIND 4.0

Q8WWY3: U4/U6 small nuclear ribonucleoprotein Prp31

General Information

Protein names
- U4/U6 small nuclear ribonucleoprotein Prp31
- Pre-mRNA-processing factor 31
- Serologically defined breast cancer antigen NY-BR-99
- U4/U6 snRNP 61 kDa protein
- Protein 61K
- hPrp31

Gene names PRPF31
Organism Homo sapiens
Protease Family
Protease ID
Chromosome location
UniProt ID Q8WWY3

4

N-termini

3

C-termini

1

Cleavages

0

Substrates

Sequence

        10         20         30         40         50         60 
MSLADELLAD LEEAAEEEEG GSYGEEEEEP AIEDVQEETQ LDLSGDSVKT IAKLWDSKMF 
        70         80         90        100        110        120 
AEIMMKIEEY ISKQAKASEV MGPVEAAPEY RVIVDANNLT VEIENELNII HKFIRDKYSK 
       130        140        150        160        170        180 
RFPELESLVP NALDYIRTVK ELGNSLDKCK NNENLQQILT NATIMVVSVT ASTTQGQQLS 
       190        200        210        220        230        240 
EEELERLEEA CDMALELNAS KHRIYEYVES RMSFIAPNLS IIIGASTAAK IMGVAGGLTN 
       250        260        270        280        290        300 
LSKMPACNIM LLGAQRKTLS GFSSTSVLPH TGYIYHSDIV QSLPPDLRRK AARLVAAKCT 
       310        320        330        340        350        360 
LAARVDSFHE STEGKVGYEL KDEIERKFDK WQEPPPVKQV KPLPAPLDGQ RKKRGGRRYR 
       370        380        390        400        410        420 
KMKERLGLTE IRKQANRMSF GEIEEDAYQE DLGFSLGHLG KSGSGRVRQT QVNEATKARI 
       430        440        450        460        470        480 
SKTLQRTLQK QSVVYGGKST IRDRSSGTAS SVAFTPLQGL EIVNPQAAEK KVAEANQKYF 
       490    
SSMAEFLKVK GEKSGLMST

Isoforms

- Isoform 2 of U4/U6 small nuclear ribonucleoprotein Prp31 - Isoform 3 of U4/U6 small nuclear ribonucleoprotein Prp31 - Isoform 4 of U4/U6 small nuclear ribonucleoprotein Prp31

Sequence View

        10         20         30         40         50         60 
MSLADELLAD LEEAAEEEEG GSYGEEEEEP AIEDVQEETQ LDLSGDSVKT IAKLWDSKMF 
        70         80         90        100        110        120 
AEIMMKIEEY ISKQAKASEV MGPVEAAPEY RVIVDANNLT VEIENELNII HKFIRDKYSK 
       130        140        150        160        170        180 
RFPELESLVP NALDYIRTVK ELGNSLDKCK NNENLQQILT NATIMVVSVT ASTTQGQQLS 
       190        200        210        220        230        240 
EEELERLEEA CDMALELNAS KHRIYEYVES RMSFIAPNLS IIIGASTAAK IMGVAGGLTN 
       250        260        270        280        290        300 
LSKMPACNIM LLGAQRKTLS GFSSTSVLPH TGYIYHSDIV QSLPPDLRRK AARLVAAKCT 
       310        320        330        340        350        360 
LAARVDSFHE STEGKVGYEL KDEIERKFDK WQEPPPVKQV KPLPAPLDGQ RKKRGGRRYR 
       370        380        390        400        410        420 
KMKERLGLTE IRKQANRMSF GEIEEDAYQE DLGFSLGHLG KSGSGRVRQT QVNEATKARI 
       430        440        450        460        470        480 
SKTLQRTLQK QSVVYGGKST IRDRSSGTAS SVAFTPLQGL EIVNPQAAEK KVAEANQKYF 
       490    
SSMAEFLKVK GEKSGLMST         10         20         30         40         50         60 
MSLADELLAD LEEAAEEEEG GSYGEEEEEP AIEDVQEETQ LDLSGDSVKT IAKLWDSKMF 
        70         80         90        100        110        120 
AEIMMKIEEY ISKQAKASEV MGPVEAAPEY RVIVDANNLT VEIENELNII HKFIRDKYSK 
       130        140        150        160        170        180 
RFPELESLVP NALDYIRTVK ELGNSLDKCK NNENLQQILT NATIMVVSVT ASTTQGQQLS 
       190        200        210        220        230        240 
EEELERLEEA CDMALELNAS KHRIYEYVES RMSFIAPNLS IIIGASTAAK IMGVAGGLTN 
       250        260        270        280        290        300 
LSKMPACNIM LLGAQRKTLS GFSSTSVLPH TGYIYHSDIV QSLPPDLRRK AARLVAAKCT 
       310        320        330        340        350        360 
LAARVDSFHE STEGKVGYEL KDEIERKFDK WQEPPPVKQV KPLPAPLDGQ RKKRGGRRYR 
       370        380        390        400        410        420 
KMKERLGLTE IRKQANRMSF GEIEEDAYQE DLGFSLGHLG KSGSGRVRQT QVNEATKARI 
       430        440        450        460        470        480 
SKTLQRTLQK QSVVYGGKST IRDRSSGTAS SVAFTPLQGL EIVNPQAAEK KVAEANQKYF 
       490    
SSMAEFLKVK GEKSGLMST         10         20         30         40         50         60 
MSLADELLAD LEEAAEEEEG GSYGEEEEEP AIEDVQEETQ LDLSGDSVKT IAKLWDSKMF 
        70         80         90        100        110        120 
AEIMMKIEEY ISKQAKASEV MGPVEAAPEY RVIVDANNLT VEIENELNII HKFIRDKYSK 
       130        140        150        160        170        180 
RFPELESLVP NALDYIRTVK ELGNSLDKCK NNENLQQILT NATIMVVSVT ASTTQGQQLS 
       190        200        210        220        230        240 
EEELERLEEA CDMALELNAS KHRIYEYVES RMSFIAPNLS IIIGASTAAK IMGVAGGLTN 
       250        260        270        280        290        300 
LSKMPACNIM LLGAQRKTLS GFSSTSVLPH TGYIYHSDIV QSLPPDLRRK AARLVAAKCT 
       310        320        330        340        350        360 
LAARVDSFHE STEGKVGYEL KDEIERKFDK WQEPPPVKQV KPLPAPLDGQ RKKRGGRRYR 
       370        380        390        400        410        420 
KMKERLGLTE IRKQANRMSF GEIEEDAYQE DLGFSLGHLG KSGSGRVRQT QVNEATKARI 
       430        440        450        460        470        480 
SKTLQRTLQK QSVVYGGKST IRDRSSGTAS SVAFTPLQGL EIVNPQAAEK KVAEANQKYF 
       490    
SSMAEFLKVK GEKSGLMST



Filter Information:


(REFRESH)

Directness:


Physiological Relevance:


Evidence Codes:


Methodology:


Perturbation of System:


Biological System:


Protease Assignment Confidence:


Evidence Names:


Database:


Lab:



Protein Neighborhood

Domains & Features

4 N-termini - 3 C-termini - 1 Cleavages - 0 Substrates

N-termini

C-termini

Cleavages

Substrates

    Substrate Position Sequence Evidence type Method Source (database) Source (Lab) Evidence name Publications (PMIDs)